ONWARD Medical Announces €40M Capital Increase with Support from EQT Life Sciences
ONWARD Medical has announced a capital increase through a private placement targeting institutional investors, aiming to raise approximately €40 million in gross proceeds. Venture capital fund EQT Life Sciences will participate in the transaction with an investment of €25 million.
The net proceeds from the private placement, combined with existing cash reserves, are expected to fund the company's operations until the first quarter of 2028, provided there are no draws on its debt facility. ONWARD Medical, specializing in neurorehabilitation technologies for individuals with spinal cord injuries and other movement disorders, has developed the ARC-EX® system, which is marketed in the United States and Europe, and an investigational implantable system, ARC-IM®, designed to address multiple unmet needs, including tension instability following spinal injury.
Details of the Offering
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The bookbuilding period begins immediately following the announcement and is expected to conclude prior to the opening of the market on Euronext Brussels, Amsterdam, and Paris around April 16, 2026. Admission and listing of the new shares are scheduled for April 20, 2026, when payment and delivery are also due to occur. The new shares will be issued with the exclusion of the pre-emptive rights of existing shareholders. Stifel is coordinating the transaction globally, with Degroof Petercam acting as co-managers. The company and certain board members have agreed to a 90-day lock-up period, subject to customary exceptions.
Launch of ARC-EX continues to be a resounding success...
Risks mentioned
Retard dans les approbations réglementaires pouvant affecter les délais.
Concurrence accrue dans le secteur de la neurotechnologie.
Opportunities identified
Lancement du système ARC-EX avec succès aux États-Unis.
Récupération de la demande soutenue pour la technologie de stimulation.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
